O
ELEV

OrbiMed’s Elevation Oncology ELEV Stock Holding History

OrbiMed’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-941,275
Closed -$530K – 113
2024
Q4 		$530K Hold
941,275
– – 0.01% 115
2024
Q3 		$565K Hold
941,275
– – 0.01% 117
2024
Q2 		$2.54M Hold
941,275
– – 0.05% 101
2024
Q1 		$4.83M Sell
941,275
-558,725
-37% -$1.81M 0.09% 97
2023
Q4 		$806K Hold
1,500,000
– – 0.02% 108
2023
Q3 		$994K Hold
1,500,000
– – 0.02% 120
2023
Q2 		$2.28M Buy
+1,500,000
New +$3.96M 0.04% 115

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed's ELEV Position: Q1 2025 in Review

OrbiMed sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 941,275 shares — an estimated $530K sold.

OrbiMed first reported a position in ELEV in Q2 2023 and held it in 7 quarters. The position peaked at $4.83M in Q1 2024. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

  • OrbiMed reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
  • OrbiMed sold 941,275 Elevation Oncology shares in Q1 2025, an estimated $530K.
  • OrbiMed first reported a position in Elevation Oncology in Q2 2023 and held it in 7 quarters.
  • OrbiMed's Elevation Oncology position peaked at $4.83M in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.